Skip to content

Clinical Benefits of the Manipulation Quantitative Science of "Xingnao Kaiqiao" Acupuncture Therapy and Its Relationship With Specific Manifestations

Clinical Benefits of the Manipulation Quantitative Science of "Xingnao Kaiqiao" Acupuncture Therapy and Its Relationship With Specific Manifestations

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000081
Enrollment
Unknown
Registered
2026-01-17
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic strok

Interventions

experimental group: "Xingnao Kaiqiao" acupuncture therapy
control group:conventional acupuncture

Sponsors

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Patients meeting the diagnostic criteria for acute ischemic stroke as outlined in the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023" published by the Chinese Medical Association's Neurology Branch 2) Stroke onset within the past 6 months; 3) National Institutes of Health Stroke Scale (NIHSS) score of 4–20 points; 4) Age: 18–80 years old; 5) Informed consent signed by the patient or their legal representative, with willingness to comply throughout the entire study process.

Exclusion criteria

Exclusion criteria: 1) CT or MRI imaging reveals hemorrhagic stroke, such as hemorrhagic stroke, subdural hematoma, intracranial hematoma, or intraventricular hemorrhage; 2) Stroke caused by brain tumors, severe traumatic brain injury, or hematologic disorders (e.g., coagulation abnormalities); 3) Transient ischemic attack (TIA), i.e., stroke without evidence of persistent neurological deficit; 4) Coma or loss of consciousness with NIHSS category 1a score > 1 point; 5) Severe cognitive impairment, advanced Parkinson's disease, or psychiatric disorders affecting patient compliance or intervention efficacy assessment; 6) Concurrent severe systemic diseases, such as uncontrolled hypertension (systolic =200 mmHg or diastolic =110 mmHg), unstable cardiac conditions (e.g., recent myocardial infarction, heart failure), compromising patient survival or treatment safety in this study; 7) Any other condition deemed by the investigator to make the patient unsuitable for study participation, such as severe needle phobia rendering the patient intolerant, pregnancy, planned pregnancy, breastfeeding, or other factors potentially affecting study outcomes.

Design outcomes

Primary

MeasureTime frame
National Institute of Health stroke scale;

Secondary

MeasureTime frame
EuroQol 5-Dimensions 5-Level;Modified Rankin Scale score;

Countries

China

Contacts

Public ContactWenyi Ge

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

gewenyi@yeah.net16622911526

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 7, 2026